Invivyd (IVVD) Share-based Compensation (2020 - 2026)
Invivyd's (IVVD) quarterly Share-based Compensation came in at $2.6 million in Q4 2025, down 16.13% YoY from $3.1 million in Q4 2024, and down 79.81% on a QoQ basis from $12.7 million in Q3 2025.
Invivyd (IVVD) Share-based Compensation (2020 - 2026) Analysis & Trends
Invivyd (IVVD) has 6 years of Share-based Compensation data on file, last reported at $2.6 million in Q4 2025.
- Quarterly Share-based Compensation fell 16.13% year-over-year to $2.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.7 million (down 41.05% YoY) and the FY2025 annual result came in at $11.6 million, down 41.16% from the prior year.
- Share-based Compensation retreated to $2.6 million in Q4 2025, from $12.7 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $19.9 million in Q4 2022 to a low of -$9.9 million in Q4 2021.
- A 5-year average of $5.6 million and a median of $4.5 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2021 — Share-based Compensation tumbled 10008.0% — and 2025, when it surged 343.13%.
- Tracing IVVD's Share-based Compensation over 5 years: stood at -$9.9 million in 2021, then surged by 301.05% to $19.9 million in 2022, then tumbled by 78.19% to $4.3 million in 2023, then declined by 29.63% to $3.1 million in 2024, then declined by 16.13% to $2.6 million in 2025.
- The last three Share-based Compensation figures came in at $2.6 million (Q4 2025), $12.7 million (Q3 2025), and $3.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Invivyd | 212.23 Mn | 52.15 Mn | 13.01 Mn | 17.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.40 Mn |
| Jun 30, 2026 | 17.40 Mn |
| Dec 31, 2025 | 2.56 Mn |
| Dec 31, 2025 | 2.56 Mn |
| Sep 30, 2025 | 12.70 Mn |
| Sep 30, 2025 | 12.70 Mn |
| Jun 30, 2025 | 3.18 Mn |
| Jun 30, 2025 | 3.18 Mn |
| Mar 31, 2025 | 19.00 Mn |
| Mar 31, 2025 | 19.00 Mn |
| Dec 31, 2024 | 3.06 Mn |
| Dec 31, 2024 | 3.06 Mn |
| Sep 30, 2024 | 2.87 Mn |
| Sep 30, 2024 | 2.87 Mn |
| Jun 30, 2024 | 8.49 Mn |
| Jun 30, 2024 | 8.49 Mn |
| Mar 31, 2024 | 5.38 Mn |
| Mar 31, 2024 | 5.38 Mn |
| Dec 31, 2023 | 4.34 Mn |
| Dec 31, 2023 | 4.34 Mn |